Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA. |  |
|
| Co-FounderDr. Gregory A. Demopulos M.D. VP of FinanceMr. David J. Borges VPMr. Peter B. Cancelmo J.D. Ph.D.Dr. Pamela Pierce Palmer M.D. Ph.D.Dr. George A. Gaitanaris M.D. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| PETER CANCELMO | Officer | Aug 28 '26 | Proposed Sale | 18.65 | 25,000 | 466,128 | | Aug 28 04:34 PM | | HANISH ARNOLD C | Director | Aug 27 '26 | Option Exercise | 14.95 | 10,000 | 149,475 | 10,000 | Aug 28 04:31 PM | | HANISH ARNOLD C | Director | Aug 26 '26 | Option Exercise | 15.81 | 5,000 | 79,050 | 5,000 | Aug 28 04:31 PM | | HANISH ARNOLD C | Director | Aug 27 '26 | Sale | 18.95 | 10,000 | 189,462 | 0 | Aug 28 04:31 PM | | HANISH ARNOLD C | Director | Aug 26 '26 | Sale | 18.53 | 5,000 | 92,632 | 0 | Aug 28 04:31 PM | | ARNOLD HANISH | Director | Aug 27 '26 | Proposed Sale | 18.95 | 10,000 | 189,462 | | Aug 27 04:12 PM | | ARNOLD HANISH | Director | Aug 26 '26 | Proposed Sale | 18.83 | 5,000 | 94,132 | | Aug 26 04:16 PM | | Borges David J. | VP, Finance & CAO | Aug 21 '26 | Option Exercise | 3.52 | 10,000 | 35,247 | 10,000 | Aug 25 05:40 PM | | Borges David J. | VP, Finance & CAO | Aug 24 '26 | Option Exercise | 2.94 | 906 | 2,664 | 906 | Aug 25 05:40 PM | | Borges David J. | VP, Finance & CAO | Aug 21 '26 | Sale | 18.95 | 10,000 | 189,500 | 0 | Aug 25 05:40 PM | | Borges David J. | VP, Finance & CAO | Aug 24 '26 | Sale | 19.10 | 906 | 17,305 | 0 | Aug 25 05:40 PM | | Cable Thomas J. | Director | Aug 20 '26 | Option Exercise | 2.96 | 15,000 | 44,475 | 50,067 | Aug 21 05:34 PM | | Cable Thomas J. | Director | Aug 20 '26 | Sale | 18.45 | 15,000 | 276,772 | 35,067 | Aug 21 05:34 PM | | DAVID BORGES | Officer | Aug 21 '26 | Proposed Sale | 18.63 | 10,906 | 203,179 | | Aug 21 04:42 PM | | THOMAS CABLE | Director | Aug 20 '26 | Proposed Sale | 18.45 | 15,000 | 276,772 | | Aug 20 04:23 PM | | Borges David J. | VP, Finance & CAO | Aug 13 '26 | Option Exercise | 3.93 | 5,000 | 19,650 | 5,000 | Aug 17 07:42 PM | | Borges David J. | VP, Finance & CAO | Aug 13 '26 | Sale | 16.95 | 5,000 | 84,750 | 0 | Aug 17 07:42 PM | | DAVID BORGES | Officer | Aug 13 '26 | Proposed Sale | 13.71 | 5,000 | 68,550 | | Aug 13 04:36 PM | | Cable Thomas J. | Director | May 22 '26 | Option Exercise | 10.84 | 7,500 | 81,300 | 42,567 | May 27 06:21 PM | | Cable Thomas J. | Director | May 22 '26 | Sale | 11.61 | 7,500 | 87,039 | 35,067 | May 27 06:21 PM | | Thomas Cable | Director | May 22 '26 | Proposed Sale | 11.96 | 7,500 | 89,700 | | May 22 04:33 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Feb 18 '26 | Option Exercise | 10.27 | 400,000 | 4,108,000 | 1,826,986 | Feb 20 09:40 PM | | Borges David J. | VP, Finance & CAO | Jan 13 '26 | Option Exercise | 3.06 | 30,000 | 91,800 | 30,000 | Jan 14 05:25 PM | | Borges David J. | VP, Finance & CAO | Jan 12 '26 | Sale | 12.72 | 30,000 | 381,600 | 0 | Jan 14 05:25 PM | | Borges David J. | VP, Finance & CAO | Jan 13 '26 | Sale | 12.31 | 30,000 | 369,315 | 0 | Jan 14 05:25 PM | | DAVID J BORGES | Officer | Jan 13 '26 | Proposed Sale | 12.31 | 30,000 | 369,315 | | Jan 13 04:31 PM | | DAVID J BORGES | Officer | Jan 12 '26 | Proposed Sale | 12.72 | 30,000 | 381,600 | | Jan 12 04:32 PM |
|
O